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The new UK antimicrobial resistance strategy and
action plan
A major societal, political, clinical, and research challenge
Anthony S Kessel honorary professor 1, Mike Sharland professor in paediatric infectious diseases 2
1Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK; 2Paediatric Infectious Diseases Research
Group, St George’s University London, London SW17 0RE, UK
This week the chief medical officer highlighted in her report
how the rise of antimicrobial resistance (AMR) poses a threat
to healthcare delivery in the United Kingdom.1 This will be
followed shortly by the Department of Health’s new UK Five
Year Antimicrobial Resistance Strategy and Action Plan, which
will reflect the need for a clear change in the understanding and
response to AMR by the public, the NHS, and the government
in the UK. The rise of AMR as a serious health threat is due to
the international spread of multidrug resistant (MDR) Gram
negative bacteria, the global overuse of antibiotics in humans
and animals, and the almost complete lack of new antibiotic
development.2 All of these are now of direct concern to the
NHS.
The 85% reduction in rates of meticillin resistant Staphylococcus
aureus (MRSA) bloodstream infections seen in England between
2003 and 2011 has been remarkable. MRSA is now responsible
for less than 2% of all bloodstream infections in England. Less
remarked on has been the inexorable rise in the number of
bloodstream infections attributable to Gram negative organisms
(particularly Escherichia coli), which now comprise more than
half of the around 100 000 of these infections reported in
England annually.3 Most large NHS hospitals now identify
50-100 times more patients with Gram negative bloodstream
infections than those with MRSA, with antibiotic resistance
rates of 10-20% and mortality rates of 30% reported for MDR
forms.4 In England the successful introduction of conjugate
pneumococcal vaccine means that the number of reported
Klebsiella pneumoniae bloodstream infections in England is
now higher than for Streptococcus pneumoniae.
In many European countries AMR rates are much worse. In
2011 the European Centre for Disease Prevention and Control
reported a significant increase in multidrug resistant E coli and
K pneumoniae (for example, resistance to third generation
cephalosporins, fluoroquinolones, and aminoglycosides) inmore
than a third of European Union/European Economic Area
countries.5 Klebsiella is an important pathogen in the spread of
resistance. Many antibiotic resistance genes group together in
plasmids easily transferred between bacteria, with particular
clones carryingmultiple resistance genes (for example, OXA-48
and CTX-M15). Many EU countries are now reporting
Klebsiella MDR rates of 25-40%.
Globally, rates of MDR Gram negative bacterial infection can
be even higher.6 This has inevitably led to a rapid rise in the use
of carbapenem antibiotics (for example, meropenem) as
empirical treatment for suspected sepsis. In turn, this has led to
a rapid increase in hospital outbreaks of carbapenemase
producing organisms, which are usually sensitive to only one
or two older less effective antibiotics. In the UK, there has also
been a sharp rise in meropenem use and increasing reports of
carbapenemase producing organisms, with worryingly both
clonal outbreaks and interspecies plasmid spread seen in some
NHS hospitals. Only one or two new antibiotics that target Gram
negative organisms are likely to be marketed in the next decade
(http://antibiotic-action.com), which raises the concern that
virtually untreatable infections will threaten routine NHS care
for vulnerable children and adults. Experts in policy analysis
describe this type of problem as a “super wicked challenge.”7
The new UK strategy is an important step in recognising and
responding to these concerns, driven by the emergence of
carbapenemase producing organisms in the NHS. At its core
the strategy recognises that AMR, infection prevention and
control, and antimicrobial stewardship are closely interconnected
and all need to be strengthened. The seven aims (table⇓) reflect
that all individuals and organisations have unique roles and
responsibilities. Enhanced infection prevention and control are
crucial to limiting the spread of MDR Gram negative bacteria,
both into and across the NHS.
New challenges will include screening (by rectal swab) and
isolation of any patient admitted to the NHS who has received
inpatient care outside the UK, with rigorous control of any
outbreaks of multidrug resistant infection inside the NHS. Acute
trusts and their boards will need to learn a new language and
consider how to strengthen infection prevention and control
practice using new methods of organisational and behavioural
change to reinforce policy implementation. Although zero
tolerance to MRSA and Clostridium difficile infection remain
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crucial, these organisms now represent only a small part of
healthcare associated infections. Enterobacteraciae (Gram
negative organisms) were the most common cause identified in
the recent national healthcare associated infections point
prevalence survey (32.4% of reported organisms v 2.4% for
MRSA).3
Antimicrobial prescribing needs to be more evidence based and
more efficiently targeted. New NHS initiatives to provide
antimicrobial stewardship guidance in secondary care (Start
Smart then Focus) and primary care (TARGET antimicrobial
toolkit)8 need to develop into more formal quality indicators.
They must emphasise that every prescriber should consider the
impact of each prescription on the individual patient and the
wider burden of AMR. The risk-benefit balance for antibiotic
prescribing is becoming even more complex; patient
expectations, clinical outcomes, and ethical issues must all be
considered.
This strategy makes the UK the first country to explicitly
announce its intention to develop national outcome measures
in AMR using specific drug-bug combination resistance rates
(for example, rates of E coli resistance to third generation
cephalosporins). This is a brave move and should be welcomed.
The chief medical officer has taken a clear leadership role by
tackling the international dimensions of the problem, adding
AMR to the Department of Health risk register and calling for
AMR to be added to the national risk register (National Security
Risk Assessment) to promote cross government action.
Important areas that will be covered include antimicrobial use
in animals and new initiatives to encourage the development of
novel antimicrobials.1
The wider application of molecular microbiology, particularly
whole genome sequencing, to detect clonal spread of MDR
Gram negative bacteria within hospitals is providing a rapid
explosion of new data. It is still unclear if this will lead to
effective new control policies. The research agenda is extensive,
but the NHS information technology and National Institute of
Health Research infrastructures are well placed to provide global
leadership in this area.9 New technology focusing on rapid
diagnosis of specific bacteria and resistance genes, along with
combination biomarkers indicating bacterial or viral infections,
especially if adapted to near patient testing, could have a major
impact on targeting appropriate antibiotic treatment. Improved
surveillance by Public Health England, using large dataset
linkage combined efficiently with observational studies focused
on clinical outcomes, including all infection related deaths, will
also help to define new targets for intervention.
The UK strategy provides a call for action. The problems are
global and the terminology complex, but the importance is clear.
Public Health England and the NHSCommissioning Board will
play major roles in implementing the strategy. A fundamental
standard of the NHS should include basic high quality routine
infection control and clinical care, as noted by the Francis
inquiry.10 These standards of care are crucial to the prevention
and control of all healthcare associated infections, including
MDR Gram negative bacteria.
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Table
Table 1| UK antimicrobial resistance strategy: seven action areas and likely stakeholder involvement in the health sector
StakeholdersSeven key areas of focus
Individual prescribers, NHS providers, national and local commissioning
boards, ARHAI, PHE, Department of Health, professional bodies
Promote responsible evidence based prescribing
Individual clinical staff, NHS providers, national and local commissioning
boards, ARHAI, Department of Health, PHE, professional bodies
Improve infection prevention and control
Professional bodies, Department of Health, ARHAI, patient groupsRaise public and professional awareness of antimicrobial resistance threat and
promote behaviour change
NIHR, universities, Department of Health, ARHAIResearch programme into new diagnostics, alternatives to antibiotics (such as
antiseptics), pathogenesis, effective behavioural change to improve infection
prevention and control and prescribing practice
Department of Health, drug industry, European UnionFacilitate development of new antimicrobials, vaccines, and immunomodulators
PHE, ARHAI, Department of HealthImprove surveillance and data linkage
Department of Health, PHEEncourage international collaboration and data sharing and learning from best practice
internationally
ARHAI=Department of Health Expert Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infection; PHE=Public Health England.
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